^Boulpaep EL, Boron, WF (2005). Medical physiology: a cellular and molecular approach. St. Louis, Mo: Elsevier Saunders. p. 1180. ISBN 1-4160-2328-3
^“Entrez Gene: CYP17A1 cytochrome P450, family 17, subfamily A, polypeptide 1”. 2014年8月15日閲覧。
^PDB: 3ruk; DeVore NM, Scott EE (February 2012). “Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001”. Nature482 (7383): 116–9. doi:10.1038/nature10743. PMC 3271139. PMID 22266943. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3271139/.
読書案内
Miura K, Yasuda K, Yanase T et al. (1996). “Mutation of cytochrome P-45017 alpha gene (CYP17) in a Japanese patient previously reported as having glucocorticoid-responsive hyperaldosteronism: with a review of Japanese patients with mutations of CYP17”. J. Clin. Endocrinol. Metab.81 (10): 3797–801. doi:10.1210/jc.81.10.3797. PMID 8855840.
Miller WL, Geller DH, Auchus RJ (1999). “The molecular basis of isolated 17,20 lyase deficiency”. Endocr. Res.24 (3–4): 817–25. doi:10.3109/07435809809032692. PMID 9888582.
Strauss JF (2004). “Some new thoughts on the pathophysiology and genetics of polycystic ovary syndrome”. Annals of the New York Academy of Sciences997: 42–8. doi:10.1196/annals.1290.005. PMID 14644808.
Haider S, Patel J, Poojari C, Neidle S (2010). “Molecular modeling on inhibitor complexes and active-site dynamics of cytochrome P450 C17, a target for prostate cancer therapy”. J. Mol Biol400 (5): 1078–098. doi:10.1016/j.jmb.2010.05.069. PMID 20595043.